Infection Risk in Myeloma: Challenges and Strategies With Bispecific Antibodies
Bispecific antibodies (BsAbs) represent a promising advancement in the treatment of multiple myeloma (MM), particularly for relapsed or refractory cases....
ANP-BC, OCN, CCRC
Associate Director, Myeloma Research, Icahn School of Medicine at Mount Sinai
Patient Management Guidelines
National Comprehensive Cancer Network Clinical Practice Guidelines
The National Comprehensive Cancer Network Clinical Practice Guidelines has evidence-based guidance on the diagnosis, workup, and management of multiple myeloma.
These guidelines provide recommendations on treatment for both patients who are newly diagnosed with multiple myeloma and patients who have relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.
FDA Endorses MRD as Surrogate Endpoint to Accelerate Myeloma Drug Approvals
The FDA’s recent acceptance of minimal residual disease (MRD) negativity as a surrogate endpoint for accelerated approval in multiple myeloma (MM) represents a major advancement in clinical trial design and...
Optimizing T-cell Therapies in Multiple Myeloma: Key Insights and Strategies
The management of multiple myeloma (MM) is evolving with the advent of T-cell redirecting therapies (TCRT), such as chimeric antigen receptor T (CAR T)-cell therapies and bispecific T-cell engagers (TCEs)....
Integrative Approaches in Multiple Myeloma: Managing Symptoms and Improving Quality of Life
Multiple myeloma (MM) has seen significant treatment advancements, including immune modulators, proteasome inhibitors, and chimeric antigen receptor T cell therapies, resulting in a tripling of median overall survival....
Balancing Efficacy and Safety: Managing Adverse Events With IMiDs in Multiple Myeloma
Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide are integral to multiple myeloma (MM) treatment, improving survival and quality of life....
High-Fiber Plant-Based Diet Delays Progression From MGUS/SMM to Multiple Myeloma in Pilot Study
Researchers of this pilot study assessed the impact of a high-fiber plant-based dietary (HFPBD) intervention on 20 patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM)....
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
